ClinicalTrials.gg
CompletedNCT03215277Updated Jul 27, 2023Results posted

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

A Phase 2 interventional study of Bimekizumab and Certolizumab pegol in Ankylosing Spondylitis, sponsored by UCB Biopharma SRL. Completed at 34 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Spondylitis, Ankylosing by UCB S.A. — none open to participants now, none under way, none of them phase 3. Spondylitis, Ankylosing · UCB S.A..

Started
2017
with 1 other
Phase 2
3 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Spondylitis, Ankylosing by UCB S.A., this one is one of 2 that started in 2017, is one of 3 in phase 2, and was the 8th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

None of the 11 studies in Spondylitis, Ankylosing by UCB S.A. is open now. The open studies under Spondylitis, Ankylosing, anywhere →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Spondylitis, Ankylosing by UCB S.A. as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • Ankylosing Spondylitis
  • Bimekizumab
  • AS
  • Certolizumab Pegol
  • Cimzia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of active adult-onset ankylosing spondylitis (AS) as defined by documented radiologic evidence (X-ray) fulfilling the Modified New York criteria for AS (1984) of at least 3 months' symptom duration and age of onset \<45 years
  • Subject has moderate to severe active disease at the Screening Visit as defined by each of the following:

    1. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >=4
    2. Spinal pain >=4 on a 0 to 10 numeric rating scale (NRS) (from BASDAI Item 2)
  • Subjects must have had an inadequate response to, have a to, or have been intolerant to at least 2 nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Subjects taking must be on a maximum daily dose of \<=10mg/day oral prednisolone or equivalent
  • Subjects taking methotrexate (MTX; \<=25 mg/week) are allowed to continue their medication if they received a stable dose for at least 12 weeks before randomization
  • Subjects taking sulfasalazine (up to 3 grams/day) or hydroxychloroquine (up to 400 mg per day total) are allowed to continue their medication if started at least 12 weeks prior to randomization
  • Subject who has been on an anti-tumor necrosis factor alpha (TNFα) agent must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months or have been intolerant to at least 1 administration of an anti-TNFα agent. Subjects may not have been on more than 1 anti-TNFα agent
  • Subject has high-sensitive C-Reactive Protein (hsCRP) levels >=3 mg/L at the Screening Visit
  • Female subjects must be , permanently sterilized or, if of , must be willing to use a highly effective method of up till 20 weeks after last administration of medicinal product (IMP)
  • Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of IMP

Exclusion criteria

Exclusion Criteria:

  • Subject has received previous or current biological treatment other than TNFα inhibitor treatment
  • Subjects with a total ankylosis of the spine, or a diagnosis of any other inflammatory arthritis eg, rheumatoid arthritis (RA), sarcoidosis, systemic lupus erythematosus, or reactive arthritis
  • Subjects with any current sign or symptom that may indicate an active infection (except for the common cold)
  • Subject has received previous or current biological treatment other than TNFα inhibitor treatment
  • Subject has chronic, recurrent, recent serious / life-threatening or current infection, as defined in the protocol
  • Subject has history of certain atypical infections, viral hepatitides, (HIV) infection, tuberculosis, as defined in the protocol
  • Subjects receiving any within the 8 weeks prior to Baseline
  • Subjects with known tuberculosis (TB) infection, at high risk of acquiring TB infection, with latent TB infection or current or history of nontuberculous mycobacteria (NTMB) infection
  • Subject has condition or treatment, recent history of (some exceptions) or demyelinating disease
  • Subjects with concurrent malignancy or a history of malignancy during the past 5 years will be excluded, with following exceptions that may be included:

    1. \<= 3 excised or ablated basal cell carcinomas of the skin
    2. One squamous cell carcinoma of the skin (stage T1 maximum) successfully excised, or ablated only (other treatments, ie, chemotherapy, do not apply), with no signs of recurrence or for more than 2 years prior to Screening
    3. Actinic keratosis (-es)
    4. Squamous cell carcinoma-in-situ of the skin successfully excised, or ablated, more than 6 months prior to Screening
  • Subject has history of psychiatric disorder, including suicidality (as defined in the protocol
  • Subject has major abnormalities on laboratory testing, as defined in the protocol
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Bimekizumab

    Subjects will receive several bimekizumab administrations on pre-defined time points. Placebo will be provided in this arm to mask the certolizumab pegol loading dose.

    Drug: Bimekizumab · Other: Placebo

  • Experimental
    Certolizumab pegol

    Subjects will receive several certolizumab pegol administrations on pre-defined time points.

    Drug: Certolizumab pegol

Interventions

  • One bimekizumab dose will be administered.

    Also known as: UCB4940, BKZ

  • Two certolizumab pegol doses will be administered. One of these doses is a loading dose.

    Also known as: CZP, Cimzia, CDP870

  • OtherPlacebo

    Placebo will be provided to maintain the blinding.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12

    ASDAS was calculated as the sum of the results from the following components: 0.121xTotal spinal pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 result), 0.058xDuration of morning stiffness (BASDAI Question 6 result), 0.110xPGADA, 0.073xPeripheral pain/swelling (BASDAI Question 3 result), 0.579x(natural logarithm of the CRP \[mg/L\] + 1), Spinal pain, PGADA, duration of morning stiffness, peripheral pain/swelling were all assessed on a numerical scale (0 to 10 units). There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 was assumed for values of hs-CRP below the LLOQ), but no defined upper score. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening. Posterior means and 95% credible intervals in each group are presented.

    Time frame: From Baseline to Week 12

  2. Number of Participants With Adverse Events (AE) During the Study Conduct

    An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A treatment-emergent adverse event (TEAE) was defined as any AE with a start date/time at the time of or after the first dose of IMP up until 140 days after the last dose of IMP.

    Time frame: From Baseline until Safety Follow-Up Visit (up to Week 64)

  3. Number of Participants With Serious Adverse Events (SAEs) During the Study Conduct

    An SAE was any untoward medical occurrence that at any dose: - Resulted in death - Is life-threatening - Required in patient hospitalisation or prolongation of existing hospitalisation - Is a congenital anomaly or birth defect - Is an infection that requires treatment with parenteral antibiotics - Other important medical events which based on medical or scientific judgement may jeopardised the participants, or may require medical or surgical intervention to prevent any of the above. A TEAE was defined as any AE with a start date/time at the time of or after the first dose of IMP up until 140 days after the last dose of IMP.

    Time frame: From Baseline until Safety Follow-Up Visit (up to Week 64)

  4. Number of Participants Who Withdrew Due to an Adverse Event (AE) During the Study Conduct

    An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as any AE with a start date/time at the time of or after the first dose of IMP up until 140 days after the last dose of IMP.

    Time frame: From Baseline until Safety Follow-Up Visit (up to Week 64)

Secondary outcomes

  1. Number of Participants With Ankylosing Spondylitis Disease Activity Score - Inactive Disease (ASDAS-ID) at Week 12

    ASDAS-ID was defined by ASDAS \< 1.3. ASDAS was calculated as the sum of the results from the following components: 0.121xTotal spinal pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 result), 0.058xDuration of morning stiffness (BASDAI Question 6 result), 0.110xPGADA, 0.073xPeripheral pain/swelling (BASDAI Question 3 result), 0.579x(natural logarithm of the CRP \[mg/L\] + 1), Spinal pain, PGADA, duration of morning stiffness, peripheral pain/swelling were all assessed on a numerical scale (0 to 10 units). There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 was assumed for values of hs-CRP below the LLOQ), but no defined upper score.

    Time frame: Week 12

  2. Number of Participants With Ankylosing Spondylitis Disease Activity Score-Major Improvement (ASDAS-MI) at Week 12

    ASDAS-MI was defined by a reduction (improvement) from Baseline in ASDAS \>=2 units. ASDAS was calculated as the sum of the results from the following components: 0.121xTotal spinal pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 result), 0.058xDuration of morning stiffness (BASDAI Question 6 result), 0.110xPGADA, 0.073xPeripheral pain/swelling (BASDAI Question 3 result), 0.579x(natural logarithm of the CRP \[mg/L\] + 1), Spinal pain, PGADA, duration of morning stiffness, peripheral pain/swelling were all assessed on a numerical scale (0 to 10 units). There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 was assumed for values of hs-CRP below the LLOQ), but no defined upper score.

    Time frame: Baseline, Week 12

07

Results

Posted Jul 27, 2023

Participant flow

The study started to enroll study participants in October 2017 and concluded in May 2020.

Participant flow — Overall Study
MilestoneCertolizumab PegolBimekizumab
Started2551
Completed2246
Not completed35
Withdrew: Adverse event23
Withdrew: Death10
Withdrew: Lost to follow-up01
Withdrew: Participant was unable to attend clinic visit01

Outcome measures

PrimaryChange From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12

ASDAS was calculated as the sum of the results from the following components: 0.121xTotal spinal pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 result), 0.058xDuration of morning stiffness (BASDAI Question 6 result), 0.110xPGADA, 0.073xPeripheral pain/swelling (BASDAI Question 3 result), 0.579x(natural logarithm of the CRP \[mg/L\] + 1), Spinal pain, PGADA, duration of morning stiffness, peripheral pain/swelling were all assessed on a numerical scale (0 to 10 units). There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 was assumed for values of hs-CRP below the LLOQ), but no defined upper score. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening. Posterior means and 95% credible intervals in each group are presented.

Time frame:
From Baseline to Week 12
Reported as:
Mean · scores on a scale
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12
scores on a scaleCertolizumab Pegol (PPS)Bimekizumab (PPS)
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12-1.83 (-2.11 to -1.55)-2.06 (-2.30 to -1.81)
Statistical analysis
  • Certolizumab Pegol (PPS) vs Bimekizumab (PPS) · Regression, Linear · Mean posterior difference: 0.23 · 95% CI -0.14 to 0.60
  • Certolizumab Pegol (PPS) vs Bimekizumab (PPS) · Regression, Linear · Pr[diff > 0%](%): 88.4
PrimaryNumber of Participants With Adverse Events (AE) During the Study Conduct

An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A treatment-emergent adverse event (TEAE) was defined as any AE with a start date/time at the time of or after the first dose of IMP up until 140 days after the last dose of IMP.

Time frame:
From Baseline until Safety Follow-Up Visit (up to Week 64)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) During the Study Conduct
ParticipantsCertolizumab Pegol (SS)Bimekizumab (SS)
Number of Participants With Adverse Events (AE) During the Study Conduct1942
PrimaryNumber of Participants With Serious Adverse Events (SAEs) During the Study Conduct

An SAE was any untoward medical occurrence that at any dose: - Resulted in death - Is life-threatening - Required in patient hospitalisation or prolongation of existing hospitalisation - Is a congenital anomaly or birth defect - Is an infection that requires treatment with parenteral antibiotics - Other important medical events which based on medical or scientific judgement may jeopardised the participants, or may require medical or surgical intervention to prevent any of the above. A TEAE was defined as any AE with a start date/time at the time of or after the first dose of IMP up until 140 days after the last dose of IMP.

Time frame:
From Baseline until Safety Follow-Up Visit (up to Week 64)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) During the Study Conduct
ParticipantsCertolizumab Pegol (SS)Bimekizumab (SS)
Number of Participants With Serious Adverse Events (SAEs) During the Study Conduct35
PrimaryNumber of Participants Who Withdrew Due to an Adverse Event (AE) During the Study Conduct

An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as any AE with a start date/time at the time of or after the first dose of IMP up until 140 days after the last dose of IMP.

Time frame:
From Baseline until Safety Follow-Up Visit (up to Week 64)
Reported as:
Count of participants · Participants
Number of Participants Who Withdrew Due to an Adverse Event (AE) During the Study Conduct
ParticipantsCertolizumab Pegol (SS)Bimekizumab (SS)
Number of Participants Who Withdrew Due to an Adverse Event (AE) During the Study Conduct33
SecondaryNumber of Participants With Ankylosing Spondylitis Disease Activity Score - Inactive Disease (ASDAS-ID) at Week 12

ASDAS-ID was defined by ASDAS \< 1.3. ASDAS was calculated as the sum of the results from the following components: 0.121xTotal spinal pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 result), 0.058xDuration of morning stiffness (BASDAI Question 6 result), 0.110xPGADA, 0.073xPeripheral pain/swelling (BASDAI Question 3 result), 0.579x(natural logarithm of the CRP \[mg/L\] + 1), Spinal pain, PGADA, duration of morning stiffness, peripheral pain/swelling were all assessed on a numerical scale (0 to 10 units). There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 was assumed for values of hs-CRP below the LLOQ), but no defined upper score.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With Ankylosing Spondylitis Disease Activity Score - Inactive Disease (ASDAS-ID) at Week 12
ParticipantsCertolizumab Pegol (PPS)Bimekizumab (PPS)
Number of Participants With Ankylosing Spondylitis Disease Activity Score - Inactive Disease (ASDAS-ID) at Week 12511
SecondaryNumber of Participants With Ankylosing Spondylitis Disease Activity Score-Major Improvement (ASDAS-MI) at Week 12

ASDAS-MI was defined by a reduction (improvement) from Baseline in ASDAS \>=2 units. ASDAS was calculated as the sum of the results from the following components: 0.121xTotal spinal pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 result), 0.058xDuration of morning stiffness (BASDAI Question 6 result), 0.110xPGADA, 0.073xPeripheral pain/swelling (BASDAI Question 3 result), 0.579x(natural logarithm of the CRP \[mg/L\] + 1), Spinal pain, PGADA, duration of morning stiffness, peripheral pain/swelling were all assessed on a numerical scale (0 to 10 units). There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 was assumed for values of hs-CRP below the LLOQ), but no defined upper score.

Time frame:
Baseline, Week 12
Reported as:
Count of participants · Participants
Number of Participants With Ankylosing Spondylitis Disease Activity Score-Major Improvement (ASDAS-MI) at Week 12
ParticipantsCertolizumab Pegol (PPS)Bimekizumab (PPS)
Number of Participants With Ankylosing Spondylitis Disease Activity Score-Major Improvement (ASDAS-MI) at Week 1211 (27.9 to 64.9)28 (46.5 to 73.6)

Adverse events

Collected over From Baseline until Safety Follow-Up Visit (up to Week 64). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Certolizumab Pegol (SS)1/25 (4%)3/25 (12%)16/25 (64%)
Bimekizumab (SS)0/51 (0%)5/51 (9.8%)27/51 (52.9%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventCertolizumab Pegol (SS)Bimekizumab (SS)
Arthritis bacterialInfections and infestations1/250/51
Lower limb fractureInjury, poisoning and procedural complications1/250/51
Myasthenia gravisNervous system disorders1/250/51
Completed suicidePsychiatric disorders1/250/51
Coronary artery stenosisCardiac disorders0/251/51
UveitisEye disorders0/251/51
PneumoniaInfections and infestations0/251/51
Lower respiratory tract infectionInfections and infestations0/251/51
Traumatic arthritisInjury, poisoning and procedural complications0/251/51
Hand fractureInjury, poisoning and procedural complications0/251/51
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCertolizumab Pegol (SS)Bimekizumab (SS)
NasopharyngitisInfections and infestations6/2510/51
DiarrhoeaGastrointestinal disorders3/250/51
Oral candidiasisInfections and infestations0/256/51
PharyngitisInfections and infestations0/255/51
Oral herpesInfections and infestations2/250/51
TonsillitisInfections and infestations2/251/51
Alanine aminotransferase increasedInvestigations2/251/51
Aspartate aminotransferase increasedInvestigations2/251/51
PeriarthritisMusculoskeletal and connective tissue disorders2/250/51
Ankylosing spondylitisMusculoskeletal and connective tissue disorders2/254/51

Baseline characteristics

Baseline Characteristics refer to Safety Set which consisted of all randomized study participants who received at least 1 dose (full or partial) of the investigational medicinal product (IMP).

Age, Categorical
Age, Categorical(Participants)Certolizumab PegolBimekizumabTotal Title
<=18 years000
Between 18 and 65 years254772
>=65 years044
Age, Continuous
Age, Continuous(years)Certolizumab PegolBimekizumabTotal Title
Mean39.7 ± 8.240.3 ± 12.540.1 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Certolizumab PegolBimekizumabTotal Title
Female4711
Male214465
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Certolizumab PegolBimekizumabTotal Title
White255176
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Certolizumab PegolBimekizumabTotal Title
Not Hispanic or Latino255176
08

Study locations

34 sites
  • As0013 908
    Ormond Beach, Florida 32174, United States
  • As0013 903
    Lincoln, Nebraska 68516, United States
  • As0013 902
    Oklahoma City, Oklahoma 73103, United States
  • As0013 906
    Memphis, Tennessee 38119, United States
  • As0013 202
    Kladno, Czechia
  • As0013 205
    Ostrava, Czechia
  • As0013 201
    Praha 2, Czechia
  • As0013 203
    Praha 3, Czechia
  • As0013 302
    Berlin, Germany
  • As0013 306
    Berlin, Germany
  • As0013 304
    Erlangen, Germany
  • As0013 303
    Hamburg, Germany
  • As0013 301
    Herne, Germany
  • As0013 405
    Athens, Greece
  • As0013 404
    Heraklion, Greece
  • As0013 401
    Patra, Greece
  • As0013 402
    Thessaloníki, Greece
  • As0013 406
    Thessaloníki, Greece
  • As0013 501
    Chisinau, Moldova, Republic of
  • As0013 601
    Amsterdam, Netherlands
  • As0013 708
    Białystok, Poland
  • As0013 709
    Kraków, Poland
  • As0013 706
    Olsztyn, Poland
  • As0013 703
    Poznań, Poland
  • As0013 702
    Toruń, Poland
  • As0013 701
    Warsaw, Poland
  • As0013 704
    Warszawa, Poland
  • As0013 707
    Wrocław, Poland
  • As0013 801
    Kazan, Russian Federation
  • As0013 803
    Kemerovo, Russian Federation
  • As0013 806
    Moscow, Russian Federation
  • As0013 807
    Moscow, Russian Federation
  • As0013 802
    Yaroslavl, Russian Federation
  • As0013 805
    Yaroslavl, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in May 2020, 31 months.

Results were first posted in Jul 2023, 3 years 2 months after primary completion. A results delay was requested in May 2021.

Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2017
First posted
Jul 12, 2017
StartActual
Oct 4, 2017
Primary completionActual
May 25, 2020
CompletionActual
May 25, 2020
Results delay requested
May 21, 2021
Results first posted
Jul 27, 2023
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03215277
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jul 12, 2017
Start date
Oct 4, 2017
Primary completion
May 25, 2020
Completion
May 25, 2020
Results posted
Jul 27, 2023
Last update
Jul 27, 2023

Study contacts

UCB Cares
study director · +1-844-599-2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bimekizumab · Certolizumab Pegol

Start the discussion